glp 1 obesidad SOCHOB Una actualización en las terapias

Common gastrointestinal effects reported with GLP-1 therapy include: Nausea (commonly reported, especially during dose escalation) Constipation or diarrhoea Abdominal discomfort or bloating Reduced appetite and early satiety Regarding bowel movement colour specifically, changes in stool colour are not listed as adverse effects in UK SmPCs for GLP-1 receptor agonists

By conducting thorough research, understanding the tirzepatide dosage charts, and working together with a qualified healthcare provider, you may increase the benefits of Zepbound while minimizing potential risks. Zepbound and Mounjaro are registered trademarks of Eli Lily

2015;86:423.e1-6

immune vs